Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Bhag Karamchandani who wrote (4264)	5/7/1998 1:19:00 PM
From: Izzy	Read Replies (1) \| Respond to of 6136

Query for Bhag: Why would the "insiders" want to buy more shares? You mention in your last post that the lack of purchases by insiders "is probably the one of the most negative indicators hurting AGPH price." See Steve's post #3894 regarding insider trades (there may have been a subsequent post, just can't find it). These people are still holding a substantial number of shares (purchased/optioned at a very low price). I don't understand why they would want to buy more shares now and why you consider this to be such a major issue in the stock's current price. These people have been waiting for years to make their money and, for the past year, they finally have been rewarded financially for their work/efforts. Kudos to them. We should have been so lucky.

To: Bhag Karamchandani who wrote (4264)	5/7/1998 2:51:00 PM
From: Peter Singleton	Read Replies (1) \| Respond to of 6136

Bhag, I think Peter Johnson was referring to AG3340 as a second generation MMP inhibitor, in the context of BBIOY's Marimastat as a first generation product. As AGPH as pointed out, there are a family of MMP's which perform a variety of functions. AG3340 has apparently a much higher therapeutic index than Marimastat. It inhibits the desired MMP's (those implicated in cancer) to a greater extent, and it minimally inhibits the MMP's that perform other, necessary, tasks.